Zevra Therapeutics
Stock Forecast, Prediction & Price Target
Zevra Therapeutics Financial Estimates
Zevra Therapeutics Revenue Estimates
Zevra Therapeutics EBITDA Estimates
Zevra Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $28.65M N/A | $10.45M -63.49% | $27.46M 162.58% | Avg: $95.57M Low: $75.99M High: $123.96M avg. 248.03% | Avg: $161.01M Low: $129.27M High: $203.45M avg. 68.47% | Avg: $236.12M Low: $189.57M High: $298.35M avg. 46.64% | Avg: $313.06M Low: $251.34M High: $395.57M avg. 32.58% |
Net Income
% change YoY
| $-8.55M N/A | $-41.54M -385.59% | $-46.04M -10.84% | Avg: $-16.69M Low: $-39.70M High: $17.37M avg. 63.74% | Avg: $34.07M Low: $-18.78M High: $54.95M avg. 304.10% | Avg: $56.65M Low: $42.13M High: $76.06M avg. 66.24% | Avg: $91.96M Low: $68.39M High: $123.47M avg. 62.32% |
EBITDA
% change YoY
| $7.97M N/A | $-24.08M -401.89% | $-48.59M -101.80% | Avg: $-58.77M Low: $-76.22M High: $-46.73M avg. -20.93% | Avg: $-99.01M Low: $-125.11M High: $-79.49M avg. -68.47% | Avg: $-145.20M Low: $-183.47M High: $-116.57M avg. -46.64% | Avg: $-192.51M Low: $-243.25M High: $-154.56M avg. -32.58% |
EPS
% change YoY
| -$0.29 N/A | -$1.2 -313.79% | -$1.3 -8.33% | Avg: -$0.41 Low: -$1.12 High: $0.49 avg. 68.46% | Avg: $0.57 Low: -$0.53 High: $1.55 avg. 237.80% | Avg: $1.6 Low: $1.19 High: $2.15 avg. 182.83% | Avg: $2.59 Low: $1.93 High: $3.48 avg. 62.32% |
Operating Expenses
% change YoY
| $18.86M N/A | $34.95M 85.33% | $74.12M 112.03% | Avg: $85.23M Low: $67.77M High: $110.54M avg. 14.99% | Avg: $143.59M Low: $115.28M High: $181.43M avg. 68.47% | Avg: $210.57M Low: $169.05M High: $266.07M avg. 46.64% | Avg: $279.18M Low: $224.14M High: $352.76M avg. 32.58% |
FAQ
What is Zevra Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 124.10% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -39.70M, average is -16.69M and high is 17.37M.
What is Zevra Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 98.93% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $75.99M, average is $95.57M and high is $123.96M.
What is Zevra Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 137.85% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$1.12, average is -$0.41 and high is $0.49.